What if I stop taking diabetes medication

What comes after metformin?

Metformin is still number 1 in the treatment of type 2 diabetes because of its good effectiveness, the low risk of hypoglycaemia and the lack of risk of weight gain. Sometimes, however, intolerance occurs or the lowering of blood sugar is insufficient. Good alternatives are available today for these cases.

Hypos taking metformin and sulfonylurea The 78-year-old Reinhold V. has had type 2 diabetes for eight years. Under 2 x 1,000 mg metformin and 1 x 6 mg glimepiride, the HbA1c is 6.3 mg / dl, the GFR is 43 ml. There is also coronary heart disease with five-fold bypass, hyperlipoproteinemia and essential hypertension. He also receives ASA 100, simvastatin 1 x 10 mg and candesartan 1 x 16 mg. He is currently reporting on frequent dizziness and sweating when exercising. Blood glucose measurements showed low values ​​of up to 48 mg / dl. Glimepiride was then discontinued and the metformin dose reduced to 2 x 500 mg. In addition, Mr. V. received the DPP4 inhibitor sitagliptin in a dose of 1 x 50 mg. After twelve weeks, the therapy goals (fasting blood glucose <140 mg / dl, postprandial blood glucose <180 mg / dl) were achieved with this medication. After six months the HbA1c was 7.1%, after one year 7.3% and was thus also within the target range. There was no evidence of hypoglycaemia or weight gain. Mr V reported that he had not noticed any dizziness or sweating while gardening for a long time. The sporadic blood sugar measurements no longer showed any blood glucose values ​​below 90 mg / dl.

Metformin is undisputedly the first-line therapy in the treatment of type 2 diabetes and, in addition to a very good reduction in HbA1c, has other positive properties that justify its priority. It reduces all-cause mortality and mortality from cardiovascular events [2], leads to weight loss, and reduces the risk of hypoglycaemia [1, 3].

Limitations in metformin therapy, such as chronic renal insufficiency, have been put into perspective [4]. In Germany, use has recently been permitted up to an eGFR of over 30 ml [5] (Table 1). Metformin can be used in chronically stable heart failure [38]. In a meta-analysis, mortality was 22% lower in heart failure patients who took metformin compared to those who did not. Caution is advised in acute or unstable heart failure [6]. Liver insufficiency is still a contraindication, although data are also available here that show significantly improved survival for patients with NASH-induced liver cirrhosis [7, 8, 9]. Metformin therapy leads to a reduction in all-cause mortality in patients with moderate CKD, CHF and CLD [10].

If the GFR is below 60, the comorbidities must be taken into account and intercurrent deterioration in kidney function in the context of an infection, an operation or the administration of diagnostic contrast agent must be taken into account, and therapy should be paused in these cases until the kidney function is checked.

How metformin works by inhibiting gluconeogenesis in the liver, improving glucose uptake in muscle cells, and reducing glucose uptake from the gut, and is not fully understood. There is an improved effect of the incretin hormones as well as further interactions, including the bile acid metabolism.

If a metformin formulation is intolerant, you should first try another preparation without lactose or with a different formulation because of the many advantages. If there is still an intolerance or if the blood sugar control under monotherapy with metformin is not sufficient, the NVL [11] (Update 2014) leaves the choice of the listed antidiabetic drugs open, so that every doctor can decide for himself which one to choose.

In combination therapy with metformin, in addition to sulfonylureas, a DPP4 inhibitor, an SGLT-2 inhibitor, a GLP-1 analogue and insulin therapy can be considered for GKV insured persons.

Sulphonylureas are prescribed less and less

The combination therapy of sulfonylureas (SU) with metformin is questioned in the NVL for safety reasons by both the DEGAM and the DDG, since the data on this medication already indicated a higher cardiovascular mortality when the NVL was drawn up [11]. Since then, additional studies and meta-analyzes have confirmed this rather than invalidating it [12]. This is why the number of SE regulations has rightly decreased significantly in recent years [13] and is playing an ever smaller role in practice.

If SU is used, the patient must be carefully informed about the risk of hypoglycaemia (dizziness, falls, food cravings, effects on road safety, etc.). B. as a result of skipping a meal. Monitoring of renal function is important because SU can accumulate and, without dose adjustment, with reduced GFR can lead to long-term hypoglycaemia with sometimes fatal outcome [14].

Insulin secretagogues such as SU or repaglinide should be discontinued at the latest when insulin therapy is started, because of the incalculable risk of hypoglycaemia in combination therapy [15].

DPP4 inhibitors as a safe and effective alternative

The DPP4 inhibitors have replaced SU in many cases and represent the majority of prescriptions in practice today - instead of, after or in addition to metformin [13]. The way these substances work depends on the increase in glucose after a meal. It takes place by inhibiting the breakdown of the body's own incretin hormone GLP, which leads to insulin secretion and lowers the blood sugar level without the risk of hypoglycaemia.

A dose adjustment is recommended in the case of reduced eGFR for sitagliptin and saxagliptin, although the therapeutic index for gliptins is large.

Side effects are very rare. A slightly increased risk of pancreatitis does not play a role in everyday clinical practice [16, 17]. A safety study [18] confirmed that the substance sitagliptin did not lead to more cardiovascular events than the comparison group, ie it provided the evidence of cardiovascular safety required in the study. The same applies to saxagliptin, whereby the hospitalization rate for heart failure was increased, but without higher mortality in the verum group [29].

The Federal Joint Committee (G-BA) again awarded the substance sitagliptin a minor additional benefit in December 2016 [19].

If non-inferiority was documented in the twelve-month data for sitagliptin compared with SU, long-term data indicate a sustained effect of the DPP4 inhibitor in contrast to SU [20]. With SU, there is a loss of effectiveness in the context of secondary failure [21], which is also supported by the later onset of insulin requirement for patients on DPP4 inhibitors compared to SU [22].

Insulin therapy: a big step

For my patients, insulin therapy is always a big change in the treatment of their type 2 diabetes, but it is a good option with high fasting blood sugar levels, which must, however, be accompanied by good diabetes education, as we give our patients the strongest blood sugar-lowering substance in the Hand we have.

The patients must be particularly well informed about the symptoms and dangers of hypoglycaemia, which, in addition to the recommendations described in the SU (see above), must also contain the instructions on how hypoglycaemia can be intercepted with rapid KH (e.g. apple juice or grape sugar). Patients should always have these emergency carbohydrates with them so that they can access them at any time. The training also includes a good introduction to blood sugar self-monitoring, which patients should ideally always have access to.

With insulin therapy, there are more hypoglycemias the longer the diabetes lasts [24], although the modern analog insulins perform better than the older molecules and formulations, depending on the course of action.

In retrospective registry studies associated with the higher risk of hypoglycaemia, more CVD events and higher mortality [25, 26, 27] and a higher thromboembolic risk [28] have been described. The cardiovascular safety of therapy with insulin glargine versus standard has been demonstrated [23].

SGLT-2 inhibitors: a milestone

The SGLT-2 inhibitors (dapagliflozin and empagliflozin in Germany) are a group of substances which, completely independent of the functionality of the remaining beta cell mass, lower blood sugar by reducing the amount of glucose filtered in the glomerulum. About 70 g more glucose are excreted in the urine every day. In addition to lowering blood sugar, this leads to an increased amount of urine of approx. 300 ml, thus to a slight depletion of volume and an associated lowering of blood pressure, also through increased sodium excretion, as well as to a loss of energy, which leads to a weight loss of approx. 3 - 5 kg of body weight leads until equilibrium is established.

The large cardiovascular safety study EMPA-REG [32] described a significant superiority for the SGLT-2 inhibitor empagliflozin in relation to the examined population.

In people with diabetes who had a cardiovascular event, a reduction in mortality, cardiovascular mortality and hospitalization for heart failure has been shown for empagliflozin regardless of the same diabetes setting in the comparison group. In addition, there was an improvement in the renal parameters. The G-BA found a considerable added benefit for this group [31].

The European Commission has approved a new version of the existing authorization for empagliflozin, according to which this SGLT-2 inhibitor can be used both to lower blood sugar and to reduce cardiovascular mortality in people with type 2 diabetes [30]. Many people with diabetes who belong to this risk group can benefit from this substance. However, the necessary education about a rather harmless but taboo side effect - balanitis or vaginitis caused by fungal infections - is a small obstacle. The prescription of this SGLT-2 inhibitor in patients with previous CV damage should be assessed as a practice specialty [33].

With SGLT-2 inhibitors, normoglycemic diabetic ketoacidosis can very rarely occur, which is a new form of a known diabetes complication and which is noteworthy as it is potentially life-threatening [34, 35].

GLP-1 analogues, an underestimated class of substances

In terms of numbers, GLP-1 analogues do not play a major role in primary care practice to this day, mostly because of the price, but also because they have to be injected subcutaneously and initially have a side effect profile with nausea, etc., which worsens adherence to therapy.

In the cardiovascular safety study (LEADER), liraglutide, like empagliflozin, led to a reduced mortality in the examined group of patients with pre-existing cardiovascular diseases or high cardiovascular risk [36].

The mode of action via an exogenous increase in the GLP level leads to increased glucose-dependent insulin secretion by the beta cell, more than with the DPP-4 inhibitors without the risk of hypoglycaemia.

Additional advantages are a weight loss of 3 - 5 kg body weight, which comes about through a central influence on the saturation center, the patient eats less and drinks less. Nausea and vomiting are mostly dose-dependent temporary side effects that occur more or less with all substances, including those that are administered weekly. A benefit assessment was not carried out for liraglutide because no AMNOG assessment procedure had to be carried out. The G-BA found an additional benefit for the substance dulaglutide, which is to be injected once a week, in patients who received dulaglutide in addition to therapy with short-acting insulin with or without metformin [37]. The weekly administration is a significant relief for many of our patients and improves adherence to therapy considerably.

Let the patient have a say in the decision-making process

In everyday practice, there is often little time to weigh the effects and side effects of drugs with type 2 diabetics. However, it is worth getting the patient on board, as they read the package insert regularly and the likelihood that they will take the medication as prescribed crucially depends on whether they feel safe and their fears are being taken seriously.

The great success of the DPP4 inhibitors can therefore be explained with the fact that the effect is strong without the risk of weight gain and hypoglycemia. Side effects are manageable and easy to take, so the time required for clarification for the family doctor is usually low.

The minor additional benefit granted by the G-BA makes prescribing economically safe in practice possible.

The significant advantage of empagliflozin for cardiovascular risk patients with type 2 diabetes, the recognized additional benefit and the specialty in practice will rightly lead to a special position for this substance in the treatment of this risk group.

The therapy of type 2 diabetes can be positively influenced in every stage of the disease by sufficient knowledge of the patient about his disease, which is why his knowledge should be refreshed again and again using the inexpensive, low-side-effect diabetes education instrument. This is the best way to influence the patient's lifestyle in terms of diet and exercise, but also to influence adherence to therapy. During group training, the patients repeatedly gain motivation and learn that they are not helpless and alone at the mercy of their illness, but can influence it themselves.

Type 2 diabetes is a vascular disease and the patient has a two to four times higher cardiovascular risk.

In addition to regulating blood sugar, regulating blood pressure (<140/8 mmHg) and lowering cholesterol (LDL <100 mg / dl) are essential goals of therapy for type 2 diabetes. Exercise and sport (> 180 min / week), weight reduction and not smoking are also extremely important goals that should be addressed by the family doctor again and again and require a high level of willingness to communicate.

1. Medscape Nephrology> ViewpointsIs Metformin Safe for Patients With Chronic Kidney Disease? Lynda Szczech, MD, MSE, January 30, 2017
2. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011; 13: 221-8. [PMID: 21205121] doi: 10.1111 / j.1463-1326.2010.01349.x
3. Bolen S, Tseng E, Hutfless S, Segal JB, Suarez-Cuervo C, Berger Z, et al. Diabetes Medications for Adults with Type 2 Diabetes: An Update. Comparative Effectiveness Review no. 173. Rockville: Agency for Healthcare Research and Quality; 2016.
4. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014; 312: 2668-75. [PMID: 25536258] doi: 10 .1001 / jama.2014.15298
5. BfArM - Risk assessment procedure - Metformin for the treatment of ... https://www.bfarm.de/SharedDocs/Risikoinformationen/.../DE/RV.../metformin.htm
6. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013; 6: 395-402. [PMID: 23508758] doi: 10.1161 / CIRCHEARTFAILURE.112 .000162
7. Ampuero J, Ranchal I, Nuñez D, Díaz-Herrero Mdel M, Maraver M, del Campo JA, et al. Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. PLoS One. 2012; 7: e49279. [PMID: 23166628] doi: 10.1371 / journal.pone.0049279
8. Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, Thereneau ™, et al. Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology. 2014; 60: 2008-16. [PMID: 24798175] doi: 10.1002 / hep .27199
9. Nkontchou G, Cosson E, Aout M, Mahmoudi A, Bourcier V, Charif I, et al. Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients. J Clin Endocrinol Metab. 2011; 96: 2601-8. [PMID: 21752887] doi: 10.1210 / jc.2010-2415
10. Matthew J. Crowley, MD, MHS; Clarissa J. Diamantidis, MD, MHS; Jennifer R. McDuffie, PhD; C. Blake Cameron, MD, MBI; John W. Stanifer, MD, MSc; Clare K. Mock, MD; Xianwei Wang, MD; Shuang Tang, PhD; Avishek Nagi, MS; Andrzej S. Kosinski, PhD; and John W. Williams Jr., MD, MHS, Clinical outcomes of metformin use in populations with CKD, CHF or CLD, Annals of Internal Medicine • Vol. 3 • 7 February 2017
11. www.deutsche-diabetes-gesellschaft.de/.../NVL_Typ-2_Therapie-lang_Apr_2014 pdf
12. C. A. Bannister, S. E. Holden, S. Jenkins-Jones, C. Morgan, J. P. Halcox, G. Schernthaner, J. Mukherjee, C. J.Currie Diabetes, Obesity and Metabolism 16: 1165-1173, 2014.
13. U.Schwabe, D.Paffrath Drug Ordinance Report 2015 DOI 10.1007 / 978-3-662-47186-9_10 Springer-Verlag Berlin Heidelberg
14. Hanefeld, M., Ganz, X. & Nolte, C. Herz (2014) 39: 312. doi: 10.1007 / s00059-014-4086-1
15. Rury R. Holman, MB, Ch.B., FRCP, Andrew J. Farmer, DM, FRCGP, Melanie J. Davies, MD, FRCP, Jonathan C. Levy, MD, FRCP, Julie L. Darbyshire, MA, M.Sc., Joanne F. Keenan, BA, and Sanjoy K. Paul, Ph.D., for the 4-T Study Group N Engl J Med 2009; 361: 1736-1747, October 29, 2009, DOI: 10.1056 / NEJMoa0905479
16. Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes Ivan Tkáč and Itamar RazDiabetes Care 2016 Sep; dc151707. https://doi.org/10.2337/dc15-1707
17. Increased Pancreatitis Risk Confirmed With Gliptins, But "That Shouldn't Stop Anyone Prescribing Them" - Medscape - Oct 27, 2016
18. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, Jennifer B. Green, MD, M. Angelyn Bethel, MD, Paul W. Armstrong, MD, John B. Buse, MD, Ph.D., Samuel S. Engel , MD, Jyotsna Garg, MS, Robert Josse, MB, BS, Keith D. Kaufman, MD, Joerg Koglin, MD, Scott Korn, MD, John M. Lachin, Sc.D., Darren K. McGuire, MD, MH Sc., Michael J. Pencina, Ph.D., Eberhard Standl, MD, Ph.D., Peter P. Stein, MD, Shailaja Suryawanshi, Ph.D., Frans Van de Werf, MD, Ph.D., Eric D. Peterson, MD, MPH, and Rury R. Holman, MB, Ch.B., for the TECOS Study Group * N Engl J Med 2015; 373: 232-242July 16, 2015DOI: 10.1056 / NEJMoa1501352
19. Benefit assessment procedure for the active ingredient sitagliptin (reassessment ... https: //www.g-ba.de/informationen/nutzenicherung/250/active ingredient: sitagliptin; trade name: Januvia®, Xelevia®; therapeutic area: diabetes mellitus type 2 (metabolic diseases );
20. Pharmacol Res. 2015 Oct; 100: 127-34. doi: 10.1016 / j.phrs.2015.07.019. Epub 2015 Jul 23. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy, Derosa G1, D‘Angelo A2, Maffioli P3.
21. Viberti, Giancarlo, et al. "A diabetes outcome progression trial (ADOPT)." Diabetes care 10-25 (2002): 1737-1743.
22. Inzucchi, S. E., et al. "Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy." Diabetes, Obesity and Metabolism 10/17 (2015): 956-964.
23. ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367: 319-328
24. UK Hypoglycaemia Study Group Diabetologia (2007) 50: 1140. doi: 10.1007 / s00125-007-0599-y
25. Nystrom, T., et al. "Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia." Diabetes research and clinical practice 123 (2016): 199.
26. Gamble, John-Michael, et al. "Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study." The Lancet Diabetes & Endocrinology 5.1 (2017): 43-52.
27. Claesen, Marc, et al. "Mortality in Individuals Treated With Glucose-Lowering Agents: A Large, Controlled Cohort Study." The Journal of Clinical Endocrinology & Metabolism 101.2 (2015): 461-469.
28. Patti, Giuseppe, et al. "Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF." Journal of the American College of Cardiology 69.4 (2017): 409-419.
29. Scirica, Benjamin M., et al. "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus." New England Journal of Medicine 369.14 (2013): 1317-1326.
30. Doctors Zeitung, January 30th, 2017, Heart Protection: Approval for Empagliflozin expanded, The European Commission has approved a new version of the existing approval for Empagliflozin (Jardiance®).
31. https://www.g-ba.de/downloads/39-261-2694/2016-09-01_AM-RL-XII_Empagliflozin_D-214_BAnz.pdf?
32. Zinman, Bernard, et al. "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes." New England Journal of Medicine 373.22 (2015): 2117-2128.
33. https://www.gkv-spitzenverband.de/krankenversicherung/.../ Wirkstoff_347265.js active ingredient, empagliflozin ... field of application, empagliflozin (Jardiance®) is used in adults with type 2 diabetes mellitus ... Practice features, details
34. Updated information on the risk of diabetic ketoacidosis during treatment with SGLT2α inhibitors 14.03.2016www.akdae.de/Arzneimittelsicherheit/Weiter/20160314.pdf
35. SGLT-2 inhibitors: Over 2000 reported "cases" with acidosis www.der-arzneimittelbrief.de/.../sglt-2-hemmer-bereits-ueber-2000-gemeldete-faelle-.
36. Marso, Steven P., et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." New England Journal of Medicine 375.4 (2016): 311-322.
37. https://www.g-ba.de/informationen/nutzenicherung/157/#tab/nutzenicherung für Dulaglutide from April 29, 2015
38. Information for professionals metformin

Specialist in internal medicine, sports medicine, diabetologist DDG
You can find more articles on similar topics here: